Seasonal influenza vaccination in patients with COPD: a systematic literature review

BMC Pulmonary Medicine

Table 3 Efficacy outcomes after one year of follow-up after seasonal influenza vaccination in patients with COPD

Reference	Country	Study design	Influenza season	Vaccine type	n	Efficacy outcome	Comment
Kositanont et al., 2004 [40]	Thailand	RCT	1997–1998^a			ARI with confirmed influenza (incidence (n/N))	Study conducted in non-epidemic years. Most circulating A/H3N2 viruses among patients with acute respiratory infections matched the vaccine strain.
				TIV	61	8.2% (5/61)
				Placebo	62	27.4% (17/62)
Wongsurakiat et al., 2004 [35]	Thailand	RCT	1997–1998^a			IR of influenza-related ARI episodes
				TIV	62	6.8 per 100 py
				Placebo	63	28.1 per 100 py (p = 0.0005)
						IR of outpatient episodes
				TIV	62	3.4 per 100 py
				Placebo	63	19.8 per 100 py (p = 0.009)
						IR of hospitalisation episode
				TIV	62	3.4 per 100 py
				Placebo	63	8.3 per 100 py (p = 0.3)
						IR of mechanical ventilation episode
				TIV	62	0
				Placebo	63	5.0 per 100 py (p = 0.1)

ARI acute respiratory illness, IR incidence rate, n number of subjects, py person years, RCT randomised controlled trail, TIV trivalent iinfluenza vaccine, Placebo Vitamin B1 injection, n/N number of subjects with the outcome indicated over the total number of subjects
Wongsurakiat et al., 2004 and Kositanont et al., 2004 describe the same RCT
^aEnrolment between June 1997 – November 1998, subjects were followed for one year after vaccination

ISSN: 1471-2466